Twenty-Two Years of Phase III Trials for Patients With Advanced Non–Small-Cell Lung Cancer: Sobering Results
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
PURPOSE: To determine the changes in clinical trials and outcomes of patients with advanced-stage non–small-cell lung cancer (NSCLC) treated on phase III randomized trials initiated in North America from 1973 to 1994. PATIENTS AND METHODS: Phase III trials for patients with advanced-stage NSCLC were identified through a search of the National Cancer Institute’s Cancer Therapy Evaluation Program database from 1973 to 1994, contact with Cooperative Groups, and by literature search of MEDLINE. Patients with advanced NSCLC treated during a similar time interval were also examined in the SEER database. Trends were tested in the number of trials, in the number and sex of patients entered on the trials, and in survival over time. RESULTS: Thirty-three phase III trials were initiated between 1973 and 1994. Twenty-four trials (73%) were initiated within the first half of this period (1973 to 1983) and accounted for 5,359 (64%) of the 8,434 eligible patients. The median number of patients treated per arm of the trials rose from 77 (1973 to 1983) to 121 (1984 to 1994) (P < .001). Five trials (15%) showed a statistically significant difference in survival between treatment arms, with a median prolongation of the median survival of 2 months (range, 0.7 to 2.7 months). CONCLUSION: Analysis of past trials in North America shows that the prolongation in median survival between two arms of a randomized study was rarely in excess of 2 months. Techniques for improved use of patient resources and appropriate trial design for phase III randomized therapeutic trials with patients with advanced NSCLC need to be developed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.1.7 · Cited by 3,850
Non-small Cell Lung Cancer Collaborative Group (1995) · BMJ · doi:10.1136/bmj.311.7010.899 · Cited by 2,850
Sandler, A. B., Nemunaitis, J., Denham, C., von Pawel, J., Cormier, Y., Gatzemeier, U., Mattson, K., Manegold, C., Palmer, M. C., Gregor, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.122 · Cited by 712
Rapp, E., Pater, J. L., Willan, A., Cormier, Y., Murray, N., Evans, W. K., Hodson, D. I., Clark, D. A., Feld, R., & Arnold, A. M. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.4.633 · Cited by 698
Bonomi, P., Kim, K., Fairclough, D., Cella, D., Kugler, J., Rowinsky, E., Jiroutek, M., & Johnson, D. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.623 · Cited by 589
Self-citationWozniak, A. J., Crowley, J. J., Balcerzak, S. P., Weiss, G. R., Spiridonidis, C. H., Baker, L. H., Albain, K. S., Kelly, K., Taylor, S. A., Gandara, D. R., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2459 · Cited by 555
Self-citationPolychemotherapy in advanced non small cell lung cancer: a meta-analysis
Bernard, J. P., Souquet, P. J., Boissel, J. P., Chauvin, F., Cellerino, R., Tumarello, D., Cormier, Y., Ganz, P. A., Kaasa, S., Pater, J. L., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)91882-m · Cited by 490
A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.
Ruckdeschel, J. C., Finkelstein, D. M., Ettinger, D. S., Creech, R. H., Mason, B. A., Joss, R., & Vogl, S. E. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.1.14 · Cited by 338
Bonomi, P. D., Finkelstein, D. M., Ruckdeschel, J. C., Blum, R. H., Green, M. D., Mason, B., Hahn, R., Tormey, D. C., Harris, J., & Comis, R. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1602 · Cited by 323
Self-citationGandara, D. R., Crowley, J., Livingston, R. B., Perez, E. A., Taylor, C. W., Weiss, G., Neefe, J. R., Hutchins, L. F., Roach, R. W., & Grunberg, S. M. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.5.873 · Cited by 150
Self-citationCrawford, J., O’Rourke, M. A., Schiller, J. H., Spiridonidis, C. H., Yanovich, S., Ozer, H., Langleben, A., Hutchins, L. F., Koletsky, A. J., Clamon, G. H., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2774 · Cited by 127
Einhorn, L. H., Loehrer, P. J., Williams, S. D., Meyers, S., Gabrys, T., Nattan, S. R., Woodburn, R., Drasga, R. E., Songer, J., & Fisher, W. B. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.7.1037 · Cited by 126
Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma
Lilenbaum, R., LANGENBERG, P. W., & Dickersin, K. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980101)82:1<116::aid-cncr14>3.0.co;2-5 · Cited by 112
Weick, J. K., Crowley, J. J., Natale, R. B., Hom, B. L., Rivkin, S. E., Coltman, C. A., Taylor, S. A., & Livingston, R. B. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.7.1157 · Cited by 90
Kris, M. G., Gralla, R. J., Kalman, L. A., et al. (1985) · Lung Cancer · doi:10.1016/s0169-5002(85)80104-5 · Cited by 78
Luedke, D. W., Einhorn, L. H., Omura, G., Sarma, P. R., Bartolucci, A. A., Birch, R., & Greco, F. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.5.886 · Cited by 77
Chen, T. T. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.19.1601 · Cited by 40
Chemotherapy for inoperable, non-small cell bronchogenic carcinoma: EST 2575, generation II.
Ruckdeschel, J. C., Mehta, C. R., Om, S., Cohen, M. H., Vogl, S. E., Koons, L. S., & Lerner, H. J. (1981) · PubMed · Cited by 19
Ruckdeschel, J. C., Day, R., Weissman, C. H., Stolbach, L. L., & Creech, R. H. (1984) · PubMed · Cited by 15
Niell, H. B., Griffin, J. P., HUNTER, R. F., Meredith, C. A., & Somes, G. W. (1989) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950170115 · Cited by 10
Cited by
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationEpidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
The Role of ABC Transporters in Clinical Practice
Leonard, G. D., Fojo, T., & Bates, S. E. (2003) · The Oncologist · doi:10.1634/theoncologist.8-5-411 · Cited by 817
Genomic signatures to guide the use of chemotherapeutics
Potti, A., Dressman, H. K., Bild, A., Riedel, R. F., Chan, G., Sayer, R., Cragun, J., Cottrill, H., Kelley, M. J., Petersen, R., et al. (2006) · Nature Medicine · doi:10.1038/nm1491 · Cited by 593
RetractedHuang, S.-F., Liu, H.-P., Li, L.-H., Ku, Y.-C., Fu, Y.-N., Tsai, H.-Y., Chen, Y.-T., Lin, Y.-F., Chang, W.-C., Kuo, H.-P., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1245 · Cited by 548
Metadata
- Authors
- Breathnach, O. S., Freidlin, B., Conley, B., Green, M. R., Johnson, D. H., Gandara, D. R., O’Connell, M., Shepherd, F. A., & Johnson, B. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-03-15
- Volume
- 19
- Issue
- 6
- Pages
- 1734-1742
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2168258970
- Cited by
- 354
- References
- 20
- FWCI
- 15.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.